echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's GnRH receptor antagonist SHR7280 tablets was approved for clinical use

    Hengrui Medicine's GnRH receptor antagonist SHR7280 tablets was approved for clinical use

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 23, Hengrui Medicine announced that it had received the "Notice of Drug Clinical Trial Approval" issued by the State Drug Administration for SHR7280 tablets, and will conduct clinical trials in the near future
    .

    SHR7280 is an oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, which can block the binding of endogenous GnRH to GnRH receptors, inhibiting the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) Synthesis and release of gonadal hormones, reducing levels of sex hormones such as testosterone and estradiol
    .
    Excessive levels of estradiol hormone can lead to the occurrence and development of uterine fibroids.
    Therefore, by regulating GnRH receptors and reducing the levels of LH and FSH, uterine fibroids can be treated

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.